Castle Biosciences
Open
$20.64
Prev. Close
$20.68
High
$20.72
Low
$20.63
Market Snapshot
$615.44M
-48.0
0.66
$332.07M
942
Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The company is headquartered in Friendswood, Texas and currently employs 883 full-time employees. The company went IPO on 2019-07-25. The firm offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. The company also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).
Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The company is headquartered in Friendswood, Texas and currently employs 883 full-time employees. The company went IPO on 2019-07-25. The firm offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. The company also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).
Recently from Cashu
Castle Biosciences Wins Genomics Innovation Award for AdvanceAD-Tx Test in Atopic Dermatitis.
Castle Biosciences, Inc. (Ticker: CSTL) has gained a significant accolade, winning the 'Genomics Innovation Award' at the 10th annual MedTech Breakthrough Awards for its AdvanceAD-Tx test. This award…
Castle Biosciences Advances Melanoma Diagnostics with DecisionDx-Melanoma at AAD Annual Meeting
Castle Biosciences Strengthens Diagnostic Innovations at AAD Annual Meeting Castle Biosciences, Inc. is making significant advancements in the field of dermatology by presenting compelling research fi…
Castle Biosciences Advances Melanoma Management with DecisionDx Test Insights at AAD Meeting
Transforming Melanoma Management: Castle Biosciences Unveils Key Findings at AAD Annual Meeting At the 2026 American Academy of Dermatology (AAD) Annual Meeting, Castle Biosciences, Inc. demonstrates…
Castle Biosciences Reports Revenue Growth Amid Financial Challenges and Ongoing Innovation Efforts
Castle Biosciences Enhances Growth Through Innovation Amid Financial Hurdles Castle Biosciences announces its Q4 earnings results, highlighting a substantial rise in revenue that underscores the compa…